Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 347Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 4Atripla

02 4Biktarvy

03 1Complera /Eviplera

04 6Complera/Eviplera

05 8Descovy

06 5Genvoya

07 8Odefsey

08 2Revenue share - Symtuza

09 5Stribild

10 3Symtuza

11 9Truvada

PharmaCompass

01

Brand Name : Biktarvy

Emtricitabine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Biktarvy

arrow
Antibody Engineering
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 7,259

2019 Revenue in Millions : 4,738

Growth (%) : 53

blank

02

Brand Name : Symtuza

Emtricitabine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Symtuza

arrow
Antibody Engineering
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 488

2019 Revenue in Millions : 379

Growth (%) : 29

blank

03

Brand Name : Truvada

Emtricitabine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Truvada

arrow
Antibody Engineering
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 1,448

2019 Revenue in Millions : 2,813

Growth (%) : -49

blank

04

Brand Name : Descovy

Emtricitabine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Descovy

arrow
Antibody Engineering
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 1,861

2019 Revenue in Millions : 1,500

Growth (%) : 24

blank

05

Brand Name : Atripla

Emtricitabine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Atripla

arrow
Antibody Engineering
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 349

2019 Revenue in Millions : 600

Growth (%) : -42

blank

06

Brand Name : Genvoya

Emtricitabine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Genvoya

arrow
Antibody Engineering
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 3,338

2019 Revenue in Millions : 3,931

Growth (%) : -15

blank

07

Brand Name : Complera/Eviplera

Emtricitabine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Complera/Eviplera

arrow
Antibody Engineering
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 269

2019 Revenue in Millions : 406

Growth (%) : -34

blank

08

Brand Name : Stribild

Emtricitabine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Stribild

arrow
Antibody Engineering
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 196

2019 Revenue in Millions : 369

Growth (%) : -47

blank

09

Brand Name : Odefsey

Emtricitabine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Odefsey

arrow
Antibody Engineering
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2020 Revenue in Millions : 1,672

2019 Revenue in Millions : 1,655

Growth (%) : 1

blank

10

Brand Name : Truvada

Emtricitabine

arrow
Antibody Engineering
Not Confirmed

Brand Name : Truvada

arrow
Antibody Engineering
Not Confirmed

Emtricitabine

Main Therapeutic Indication : Infectious Diseases

Currency : USD

2021 Revenue in Millions : 371

2020 Revenue in Millions : 1,448

Growth (%) : -74

blank